Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME (BRUNELLO)

9. november 2026 opdateret af: EyeBiotech Ltd.

En randomiseret, dobbeltmaskeret, multicenter, 3-arm pivotal fase 2/3-undersøgelse til evaluering af effektiviteten og sikkerheden af ​​Intravitreal EYE103 sammenlignet med Intravitreal Ranibizumab (0,5 mg) hos deltagere med diabetisk makulaødem

EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of remigromig (EYE103) in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME)

In the first year, all 3 treatment groups will be treated every 4 weeks with either remigromig or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval algorithm.

Approximately 960 participants will be entered in the study.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of remigromig in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME)

Approximately 960 participants will be entered in the study. Participants will be randomized 1:1:1 to receive low dose remigromig, high dose remigromig, or 0.5 mg ranibizumab, administered via intravitreal injection. In the first year, all 3 treatment groups will be treated every 4 weeks with either remigromig or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval (PTI) algorithm. Throughout the 2-year study, subjects will be evaluated every 4 weeks, including measurement of Early Treatment of Diabetic Retinopathy Study (ETDRS) Best-Corrected Visual Acuity (BCVA), examination by slit-lamp biomicroscopy, fundoscopy, and spectral domain optical coherence tomography (SD-OCT). Among other parameters, SD-OCT will be used to measure central subfield thickness (CST) in microns.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

984

Fase

  • Fase 2
  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • CABA, Argentina, 1023
        • Buenos Aires, Argentina
      • Córdoba, Argentina, X5000AAJ
        • Ciudad de Cordoba, Argentina
    • Buenos Aires
      • CABA, Buenos Aires, Argentina, 1015
        • Buenos Aires, Argentina
      • CABA, Buenos Aires, Argentina, 1120
        • Buenos Aires, Argentina
      • CABA, Buenos Aires, Argentina, C1033AAW
        • Buenos Aires, Argentina
      • Caba, Buenos Aires, Argentina, C1116ABA
        • Caba, Buenos Aires, Argentina
    • Córdoba Province
      • Córdoba, Córdoba Province, Argentina, 5000
        • Cordoba, Argentina
    • Santa Fe Province
      • Rosario, Santa Fe Province, Argentina, S2000DSK
        • Santa Fe, Argentina
    • Sante Fe
      • Rosario, Sante Fe, Argentina, 2000
        • Santa Fe, Argentina
      • Albury, Australien, 2640
        • Albury, Australia
      • Parramatta, Australien, 2150
        • Parramatta, Australia
      • Sydney, Australien, 2000
        • Sydney, Australia
    • New South Wales
      • Sydney, New South Wales, Australien, 2000
        • Sydney Retina Clinic
      • Sydney, New South Wales, Australien, 2135
        • Sydney, Australia
      • Medellín, Colombia, 50016
        • Medellin, Colombia
    • Antioquia
      • Medellín, Antioquia, Colombia, 50021
        • Medellin, Colombia
    • Atlántico
      • Barranquilla, Atlántico, Colombia, 80002
        • Barranquilla, Colombia
    • Columbia
      • Bogotá, Columbia, Colombia, 110231
        • Bogota, Columbia
    • Valle del Cauca Department
      • Cali, Valle del Cauca Department, Colombia, 760042
        • Cali, Colombia
      • Bradford, Det Forenede Kongerige, BD9 6RJ
        • Bradford, United Kingdom
      • Bristol, Det Forenede Kongerige, BS1 2LX
        • Bristol, UK
      • Liverpool, Det Forenede Kongerige, L7 8YA
        • Liverpool, United Kingdom
      • Sunderland, Det Forenede Kongerige, SR2 9HP
        • Sunderland, United Kingdom
      • Wolverhampton, Det Forenede Kongerige, WV10 0QP
        • Wolverhamptom, United Kingdom
    • Middlesex
      • London, Middlesex, Det Forenede Kongerige, NW10 7NS
        • London, UK
    • UnitedKingdom
      • York, UnitedKingdom, Det Forenede Kongerige, YO10 4DZ
        • York, United Kingdom
    • Arizona
      • Scottsdale, Arizona, Forenede Stater, 85255
        • Scottsdale
    • Arkansas
      • Fayetteville, Arkansas, Forenede Stater, 72703
        • Fayetteville, Arkansas
      • Springdale, Arkansas, Forenede Stater, 72764
        • Springdale, Arkansas
    • California
      • Bakersfield, California, Forenede Stater, 93309
        • Bakersfield, CA
      • Glendale, California, Forenede Stater, 91204
        • Glendale, CA
      • Modesto, California, Forenede Stater, 95356
        • Modesto, CA
      • Mountain View, California, Forenede Stater, 94040
        • Mountain View, CA
      • Redlands, California, Forenede Stater, 92374
        • Redlands, CA
      • Sacramento, California, Forenede Stater, 95825
        • Sacramento, CA
      • Sacramento, California, Forenede Stater, 95841
        • Sacramento, CA
      • Santa Ana, California, Forenede Stater, 92705
        • Santa Ana
    • Colorado
      • Colorado Springs, Colorado, Forenede Stater, 80909
        • Colorado Springs, CO
      • Denver, Colorado, Forenede Stater, 80210
        • Denver, Colorado
    • Connecticut
      • Danbury, Connecticut, Forenede Stater, 06810
        • Danbury, CT
      • Manchester, Connecticut, Forenede Stater, 06042
        • Manchester, CT
      • Waterford, Connecticut, Forenede Stater, 06385
        • Waterford,CT
    • Florida
      • Deerfield Beach, Florida, Forenede Stater, 33064
        • Deerfield Beach, FL
      • Fort Lauderdale, Florida, Forenede Stater, 33308
        • Fort Lauderdale, FL
      • Fort Myers, Florida, Forenede Stater, 33912
        • Fort Myers,FL
      • Gainesville, Florida, Forenede Stater, 32607
        • Gainesville, FL
      • Orlando, Florida, Forenede Stater, 32806
        • Orlando, Florida
      • Plantation, Florida, Forenede Stater, 33324
        • Plantation, FL
      • Sarasota, Florida, Forenede Stater, 34232
        • Sarasota, FL
      • St. Petersburg, Florida, Forenede Stater, 33711
        • Saint Petersburg, FL
      • Tallahassee, Florida, Forenede Stater, 32308
        • Tallahassee, FL
      • Tampa, Florida, Forenede Stater, 33609-4614
        • Tampa, FL
      • Tampa, Florida, Forenede Stater, 33617
        • Tampa, FL
      • Winter Haven, Florida, Forenede Stater, 33880
        • Winter Haven, FL
    • Illinois
      • Lemont, Illinois, Forenede Stater, 60439
        • Lemont, IL
      • Springfield, Illinois, Forenede Stater, 62702
        • Springfield, Illinois
    • Iowa
      • West Des Moines, Iowa, Forenede Stater, 50266
        • West Des Moines, IA
    • Kansas
      • Lenexa, Kansas, Forenede Stater, 66215
        • Lenexa, Kansas
      • Wichita, Kansas, Forenede Stater, 67214
        • Wichita, Kansas
    • Maine
      • Portland, Maine, Forenede Stater, 04101
        • Portland, Maine
    • Maryland
      • Hagerstown, Maryland, Forenede Stater, 21740
        • Hagerstown, MD
    • Massachusetts
      • Springfield, Massachusetts, Forenede Stater, 01107
        • Springfield,MA
    • Michigan
      • Grand Rapids, Michigan, Forenede Stater, 49546
        • Grand Rapids, Michigan
    • Minnesota
      • Minneapolis, Minnesota, Forenede Stater, 55435
        • Minneapolis, MN
    • Mississippi
      • Madison, Mississippi, Forenede Stater, 39110
        • Madison, MS
    • New Jersey
      • Bloomfield, New Jersey, Forenede Stater, 07003
        • Bloomfield, NJ
      • Cherry Hill, New Jersey, Forenede Stater, 08034
        • Cherry Hill, NJ
    • New York
      • Liverpool, New York, Forenede Stater, 13088
        • Liverpool, NY
      • Oceanside, New York, Forenede Stater, 11572
        • Oceanside, NY
      • Rochester, New York, Forenede Stater, 14620
        • Rochester, NY
    • North Carolina
      • Asheville, North Carolina, Forenede Stater, 28803
        • Asheville, NC
      • Hickory, North Carolina, Forenede Stater, 28602
        • Hickory, NC
      • Wake Forest, North Carolina, Forenede Stater, 27587
        • Wake Forest, MC
      • Winston-Salem, North Carolina, Forenede Stater, 27103
        • Winston Salem, NC
    • Ohio
      • Cleveland, Ohio, Forenede Stater, 44122
        • Cleveland, Ohio
      • Cleveland, Ohio, Forenede Stater, 44130
        • Cleveland, OH
      • Youngstown, Ohio, Forenede Stater, 44505
        • Youngstown, Ohio
    • Oklahoma
      • Edmond, Oklahoma, Forenede Stater, 73013
        • Edmond, OK
    • Oregon
      • Portland, Oregon, Forenede Stater, 97221
        • Portland, OR
      • Springfield, Oregon, Forenede Stater, 97477
        • Springfield, Oregon
    • Pennsylvania
      • Bethlehem, Pennsylvania, Forenede Stater, 18017
        • Bethlehem, PA
      • Erie, Pennsylvania, Forenede Stater, 16507
        • Erie, PA
    • South Carolina
      • Beaufort, South Carolina, Forenede Stater, 29902
        • Beaufort, SC
      • Florence, South Carolina, Forenede Stater, 29501
        • Florence, SC
      • Ladson, South Carolina, Forenede Stater, 29456
        • Ladson, SC
      • West Columbia, South Carolina, Forenede Stater, 29169
        • West Columbia, SC
    • Tennessee
      • Germantown, Tennessee, Forenede Stater, 38138
        • Germantown, TN
      • Hixson, Tennessee, Forenede Stater, 37343
        • Hixson, Tennessee
      • Johnson City, Tennessee, Forenede Stater, 37604
        • Johnson City, Tennessee
      • Knoxville, Tennessee, Forenede Stater, 37922
        • Knoxville, TN
      • Nashville, Tennessee, Forenede Stater, 37203
        • Nashville, TN
    • Texas
      • Abilene, Texas, Forenede Stater, 79606
        • Abilene, TX
      • Amarillo, Texas, Forenede Stater, 79109
        • Amarillo, TX
      • Amarillo, Texas, Forenede Stater, 79106
        • Amarillo, TX
      • Arlington, Texas, Forenede Stater, 76012
        • Arlington, TX
      • Austin, Texas, Forenede Stater, 78705
        • Austin, TX
      • Beaumont, Texas, Forenede Stater, 77707
        • Beaumont, TX
      • Bellaire, Texas, Forenede Stater, 77401
        • Bellaire, TX
      • Dallas, Texas, Forenede Stater, 75231
        • Dallas, TX
      • Fort Worth, Texas, Forenede Stater, 76104
        • Fort Worth, TX
      • Katy, Texas, Forenede Stater, 77494
        • Katy, TX
      • Plano, Texas, Forenede Stater, 75075
        • Plano, TX
      • Round Rock, Texas, Forenede Stater, 78681
        • Round Rock, TX
      • San Antonio, Texas, Forenede Stater, 78240
        • San Antonio, TX
      • Schertz, Texas, Forenede Stater, 78154
        • Schertz, Texas
      • The Woodlands, Texas, Forenede Stater, 77384
        • The Woodlands, TX
      • Willow Park, Texas, Forenede Stater, 76087
        • Willow Park, TX
    • Utah
      • Salt Lake City, Utah, Forenede Stater, 84107
        • Salt Lake City, Utah
    • Virginia
      • Lynchburg, Virginia, Forenede Stater, 24502
        • Lynchburg, VA
      • Richmond, Virginia, Forenede Stater, 23235
        • Richmond, Virginia
    • Washington
      • Spokane, Washington, Forenede Stater, 99204
        • Spokane, WA
      • Créteil, Frankrig, 94010
        • Creteil, France
      • Lyon, Frankrig, 69004
        • Lyon, France
      • Marseille, Frankrig, 13008
        • Marseille, France
      • Paris, Frankrig, 75006
        • Paris, France
      • Paris, Frankrig, 75015
        • Paris, France
      • Paris, Frankrig, 75019
        • Paris, France
      • Saint-Cyr-sur-Loire, Frankrig, 37540
        • Saint Cyr sur Loire, France
    • Cedex
      • Dijon, Cedex, Frankrig, 21079
        • Cedex, France
      • Be’er Ya‘aqov, Israel, 70300
        • Beer Yakov, Israel
      • Haifa, Israel, 3436212
        • Haifa, Israel
      • Jerusalem, Israel, 9112001
        • Jerusalem, Israel
      • Petah Tikva, Israel, 49100
        • Petah Tikva, Israel
      • Rehovot, Israel, 76100
        • Rehovot, Israel
      • Tel Aviv, Israel, 6423906
        • Tel Aviv, Israel
      • Bologna, Italien, 40138
        • Bologna, Italy
      • Florence, Italien, 50139
        • Firenze, Italy
      • Milan, Italien, 20122
        • Milano, Italy
      • Milan, Italien, 20132
        • Milano, Italy
      • Milan, Italien, 20157
        • Milano, Italy
      • Roma, Italien, 00168
        • Roma, Italy
      • Rome, Italien, 81.00133
        • Rome, Italy
      • Udine, Italien, 33100
        • Udine, Italy
      • Osijek, Kroatien, 31000
        • Osijek, Croatia
      • Riga, Letland, LV1002
        • Riga, Latvia
      • Riga, Letland, LV1006
        • Riga, Latvia
      • Bialystok, Polen, 15-866
        • Bialystok, Poland
      • Bydgoszcz, Polen, 85-309
        • Bydgoszcz, Poland
      • Bydgoszcz, Polen, 85-631
        • Bydgoszcz, Poland
      • Gdansk, Polen, 80-809
        • Gdansk, Poland
      • Katowice, Polen, 40-594
        • Katowice, Poland
      • Krakow, Polen, 31-501
        • Krakow, Poland
      • Olsztyn, Polen, 10-424
        • Olsztyn, Poland
      • Tarnowskie Góry, Polen, 42-600
        • Tarnowskie Gory, Poland
    • Gdansk
      • Gdansk, Gdansk, Polen, 80-809
        • Gdansk, Poland
      • Coimbra, Portugal, 3000-548
        • Coimbra, Portugal
      • Coimbra, Portugal, 3030-163
        • Coimbra, Portugal
      • Porto, Portugal, 4200-319
        • Porto, Portugal
    • PR
      • Arecibo, PR, Puerto Rico, 00612
        • Arecibo, PR
      • Trebišov, Slovakiet, 075 01
        • Trebisov, Slovakia
      • Trenčín, Slovakiet, 911 01
        • Trencin, Slovakia
      • Žilina, Slovakiet, 012 07
        • Zilina, Slovakia
      • Barcelona, Spanien, 08035
        • Barcelona, Spain
      • Barcelona, Spanien, 08021
        • Barcelona, Spain
      • Barcelona, Spanien, 08022
        • Barcelona, Spain
      • Barcelona, Spanien, 08195
        • Barcelona, Spain
      • Santiago de Compostela, Spanien, 15706
        • Santiago de Compostela, Spain
      • Seville, Spanien, 41009
        • Sevilla, Spain
      • Zaragoza, Spanien, 50009
        • Zaragoza, Spain
    • Valencia
      • Burjassot, Valencia, Spanien, 46100
        • Valencia, Spain
      • Mladá Boleslav, Tjekkiet, 293 01
        • Mlada Boleslav, Czechia
      • Náchod, Tjekkiet, 547 01
        • Nachod, Czechia
      • Prague, Tjekkiet, 1150/50
        • Prague, Czechia
      • Prague, Tjekkiet
        • Prague, Czechia
    • Turkey
      • Ankara, Turkey, Tyrkiet (Türkiye), 06230
        • Ankara, Turkey
      • Ankara, Turkey, Tyrkiet (Türkiye), 06490
        • Ankara, Turkey
      • Balçova, Turkey, Tyrkiet (Türkiye), 35330
        • Balcova, Turkey
      • Frankfurt, Tyskland, 60590
        • Frankfurt, Germany
      • Hanover, Tyskland, 30625
        • Hanover, Germany
      • München, Tyskland, 80336
        • Munchen, Germany
      • Münster, Tyskland, 48145
        • Munster, Germany
      • Budapest, Ungarn, H-1062
        • Budapest, Hungary
      • Budapest, Ungarn, H-1085
        • Budapest, Hungary
      • Budapest, Ungarn, H-1106
        • Budapest, Hungary
      • Budapest, Ungarn, H-1133
        • Budapest, Hungry
      • Debrecen, Ungarn, H-4032
        • Debrecen, Hungary
      • Pécs, Ungarn, H-7621
        • Pecs, Hungary
      • Szeged, Ungarn, H-6720
        • Szeged, Hungary
      • Zalaegerszeg, Ungarn, 8900
        • Zalaegerszeg, Hungary
      • Graz, Østrig, 8036
        • Graz, Austria
      • Innsbruck, Østrig, 6020
        • Innsbruck, Austria
      • Vienna, Østrig, 1090
        • Vienna, Austria
      • Vienna, Østrig, 1140
        • Vienna, Austria

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Be willing and able to understand the study procedures and the risks involved and provide written informed consent before the first study-related activity
  • Be male or female ≥18 years of age.
  • Have type 1 or type 2 diabetes mellitus and a hemoglobin A1c (HbA1c) of ≤12%.
  • Have a decrease in vision in the study eye determined by the investigator to be primarily the result of diabetic macular edema (DME).

Exclusion Criteria:

  • Be pregnant or breastfeeding

  • History of cataract surgery and/or minimally invasive glaucoma surgery in the study eye within 90 days of Screening

  • Have any treatment for complications of cataract surgery with steroids or yttrium aluminum garnet (YAG) laser capsulotomy within 90 days of Screening

  • Are currently using drugs with known retinal toxicity (e.g., Hydroxychloroquine, pentosan polysulfate sodium, and amiodarone)

  • If treatment-experienced for DME have a history of any of the following treatments within the noted time windows:

    • Have had prior treatment in the study eye with 8 mg aflibercept (EYLEA HD) or faricimab (VABYSMO) within 120 days prior to the Screening visit in the study eye
    • Have had an IVT with other anti-VEGF treatments (ranibizumab, bevacizumab, aflibercept [2 mg], brolucizumab, pegaptanib sodium) in the study eye within 90 days of the Screening visit

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Remigromig Low Dose Treatment Arm

Remigromig Low Dose Treatment Arm

Remigromig is a humanized antibody formulated for intravitreal administration

Andre navne:
  • Gendan
  • EYE103
Eksperimentel: Remigromig High Dose Treatment Arm

Remigromig High Dose Treatment Arm

Remigromig is a humanized antibody formulated for intravitreal administration

Andre navne:
  • Gendan
  • EYE103
Aktiv komparator: Ranibizumab Treatment Arm

Ranibizumab Treatment Arm

Ranibizumab is a commercially available anti-VEGF treatment formulated for intravitreal administration for use in patients with diabetic macular edema

Andre navne:
  • Lucentis

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change from baseline in Best-Corrected Visual Acuity (BCVA) measured using the standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) chart
Tidsramme: Baseline and Week 52

The change from baseline in Best-Corrected Visual Acuity (BCVA) measured using the standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) chart will be presented.

Baseline and Week 52

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change from Baseline in Optical Coherence Tomography (OCT) Central Subfield Thickness (CST) at Week 52
Tidsramme: Baseline and Week 52

The change from baseline in Optical Coherence Tomography (OCT) Central Subfield Thickness (CST) at Week 52 will be presented.

Baseline and Week 52
Superiority Hypothesis: Change from Baseline in ETDRS BCVA at Week 52
Tidsramme: Baseline and Week 52

The Superiority Hypothesis: change from baseline in Early Treatment of Diabetic Retinopathy Study (ETDRS) Best-Corrected Visual Acuity (BCVA) at Week 52 will be presented.

Baseline and Week 52
Time to Absence of Diabetic Macular Edema (DME)
Tidsramme: Up to approximately Week 104

The time to absence of Diabetic Macular Edema (DME) defined as Optical Coherence Tomography (OCT) Central Subfield Thickness (CST) of <300 μm will be presented.

Up to approximately Week 104
Time to Gaining ≥15 ETDRS letters
Tidsramme: Up to approximately Week 52

The time to gaining ≥15 letters on the standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) chart will be presented.

Up to approximately Week 52
Proportion of Participants with Resolution of Macular Leakage on FA at Week 24
Tidsramme: Up to approximately Week 24

The proportion of participants with resolution of macular leakage on fluorescein angiography (FA), defined as 0 to 1 mm^2, at Week 24 will be presented.

Up to approximately Week 24
Proportion of Participants Without Intraretinal and Subretinal Fluid at the Foveal Center on OCT at Week 52
Tidsramme: Up to approximately Week 52

The proportion of participants without intraretinal and subretinal fluid at the foveal center on Optical Coherence Tomography (OCT) at Week 52 will be presented.

Up to approximately Week 52
Change from Baseline in Focal Area Zone (FAZ) area on fluorescein angiography (FA) at Week 52
Tidsramme: Baseline and Week 52

The change from baseline in Focal Area Zone (FAZ) area on fluorescein angiography (FA) at Week 52 will be presented.

Baseline and Week 52
Proportion of Participants Achieving 20/40 or Better BCVA at Week 52
Tidsramme: Up to approximately Week 52

The proportion of participants who achieve 20/40 or better Best-Corrected Visual Acuity (BCVA) at Week 52 will be presented.

Up to approximately Week 52
Number of Participants Who Experience an Ocular and/or Systemic Adverse Event (AE)
Tidsramme: Up to approximately 104 Weeks

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an ocular and/or systemic AE will be reported.

Up to approximately 104 Weeks
Number of Participants Who Experience an Ocular and/or Systemic Serious Adverse Event (SAE)
Tidsramme: Up to approximately 104 Weeks

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an ocular and/or systemic serious adverse event (SAE) will be reported.

Up to approximately 104 Weeks
Number of Participants Who Discontinue Study Treatment Due to an AE
Tidsramme: Up to approximately 104 Weeks

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported.

Up to approximately 104 Weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: Charles Miller, MD PhD, EyeBiotech Ltd.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

7. august 2024

Primær færdiggørelse (Faktiske)

14. juli 2026

Studieafslutning (Anslået)

14. august 2027

Datoer for studieregistrering

Først indsendt

20. august 2024

Først indsendt, der opfyldte QC-kriterier

22. august 2024

Først opslået (Faktiske)

26. august 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

10. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

9. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • EYE-RES-102
  • MK-3000-001 (Anden identifikator: MSD)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .